Navigation Links
option in Medical Technology

Breast Cancer Patients May Have a New Treatment Option When Cancer Spreads

New procedure could offer a safer, more convenient treatment for spine tumors LAS VEGAS, Feb. 22 /PRNewswire-USNewswire/ -- For orthopaedic researcher Joyce Keyak, Ph.D., finding ways to battle breast cancer is a personal as well as a professional mission. Her cousin died from the disease sev...

Cephalon Signs Option Agreement to Acquire Ception Therapeutics

Promising Monoclonal Antibody In Late- Stage Clinical Trial for the Treatment of Pediatric Eosinophilic Esophagitis FRAZER, Pa. and MALVERN, Pa., Jan. 13 /PRNewswire-FirstCall/ -- Cephalon, Inc . (Nasdaq: CEPH ) and Ception Therapeutics, Inc., a privately held biopharmaceutical company,...

New Analyses Indicate that Divigel(R) (estradiol gel) 0.1% Is a Valuable Option for Certain Postmenopausal Women With Hot Flashes

- Transdermal Estrogen Analyses Continue to Show Benefits of Hormone Therapy Use in Menopausal Women - MAPLE GROVE, Minn., Sept. 25 /PRNewswire/ -- Upsher-Smith Laboratories, Inc. today announced that clinical abstracts featuring Divigel(R) (estradiol gel) 0.1% were present...

Electronic Brachytherapy a Viable Option for Early Stage Breast Cancer, According to Study Presented at ASCO Breast Cancer Symposium

Researcher Says, New Non-Isotope Based Delivery System Has Potential to Help Solve Radiation Therapy Access and Treatment Disparities Reported at ASCO Symposium WASHINGTON, Sept. 8 /PRNewswire/ -- Early clinical experience with the FDA cleared Axxent(R) Electronic ...

SCAI: SYNTAX Data Show PCI Is a Good Option for Patients With Complex Coronary Artery Disease

One-Year Data Find Angioplasty and Stenting Safe and Effective in Patients for Whom Standard Therapy Has Been Open-Heart Surgery WASHINGTON, Sept. 1 /PRNewswire/ -- Data announced today from the landmark SYNTAX trial indicate that patients with very complex coronary artery disease can s...

ABC News NIGHTLINE Features HIFU with Sonablate(R) 500 as Non Invasive Treatment Option for Prostate Cancer

Segment fails to mention ongoing FDA-approved HIFU clinical trials in the United States and abundant clinical data on HIFU outcomes and experience CHARLOTTE, N.C., June 27 /PRNewswire/ -- USHIFU, LLC, the exclusive distributor of the minimally invasive Sonablate(R) 500 for prostate cancer tre...

Roche Exercises its Option to Further Develop and Commercialize Memory Pharmaceuticals' Nicotinic Alpha-7 Agonist, MEM 3454

-Memory Receives $6 Million Milestone Payment- -Memory to Host Conference Call at 9:00 a.m. EDT Today- MONTVALE, N.J. and BASEL, Switzerland, May 2 /PRNewswire-FirstCall/ -- Memory Pharmaceuticals Corp. (Nasdaq: MEMY ) and Roche (SWX: ROG) today announced that Roche has ex...

Portrait(R) Plasma - A New Non-Surgical Option for one of the Most Requested Aesthetic Treatment - Aging Eyes

Doctors Are Combining Portrait(R) Plasma with Fractionated Lasers Or in Place of Surgery to Alleviate the Signs of Aging of the Eyes WALTHAM, Mass., Jan. 24 /PRNewswire/ -- When it comes to the aging eye area, going under the knife is no longer the only option. According to the American A...

GSK Does Not Option XL784 for Further Development

SOUTH SAN FRANCISCO, Calif., Jan. 18 /PRNewswire-FirstCall/ -- Exelixis, Inc. (Nasdaq: EXEL ) today announced that GlaxoSmithKline (GSK) has decided not to exercise its option to license XL784 for further development and commercialization. Exelixis previously announced that XL784 failed to me...

New AVAC Report on Pre-Exposure Prophylaxis Calls for Immediate Planning to Anticipate Study Results of Potential New HIV Prevention Option

Now is the time to anticipate and plan for various study outcomes MEXICO CITY, Aug. 3 /PRNewswire/ -- The AIDS Vaccine Advocacy Coalition (AVAC) today released a new report, Anticipating the Results of PrEP Trials, calling for increased action from governments, global health institutions, d...

Data Suggest that Pegasys May be an Option in Hepatitis C Patients Unable to Tolerate Peg-Intron

WASHINGTON--(BUSINESS WIRE)--May 21, 2007 - Roche today announced results of a small study demonstrating that all patients who discontinued treatment with Peg-Intron(R) (peginterferon alfa-2b) and ribavirin due to adverse events within the first 12 weeks, were able to complete 12 weeks of treatment...

Merck at ASCO 2007: New Data Demonstrate the Value of UFT as an Important Treatment Option for Patients With Metastatic Colorectal Cancer

CHICAGO/DARMSTADT, Germany, June 4, 2007 – Data presented today at this year’s American Society of Clinical Oncology (ASCO) meeting in Chicago show that a novel combination regimen based on Merck KGaA’s oral 5-fluorouracil (5-FU) therapy UFT (tegafur–uracil) plus leucovorin...

Video: FDA Approves INVEGA(R) SUSTENNA(TM) for the Acute and Maintenance Treatment of Schizophrenia

...rsity of Cincinnati College of Medicine. "The approval of once-monthly INVEGA(R) SUSTENNA(TM) will provide healthcare professionals with a treatment option that is, at the same time, a definitive monitoring tool for uninterrupted medication compliance, which may help optimize clinical outcomes in schizoph...

Shire Reports Positive Results From First of Three Phase III Trials of velaglucerase alfa for Type 1 Gaucher Disease and Provides Important Updates on Interactions With FDA

...yal Free Hospital, London. "Velaglucerase alfa appears to be an excellent choice for Type 1 Gaucher patients. The prospect of having another treatment option available to help patients achieve therapeutic goals is very important and is welcomed by both the physicians and patients." Regulatory Updates...

Is Your Hair Taking a Break?

...for hair to grow out to its full density. "Minoxidil is a wonderful option for women with thinning hair, as it only treats the hair you want to keep t... cellular level of the hair follicle. These oral medications also may be an option for women who may not want to spend time applying minoxidil every day. Dr. ...

First Skin Cancer Patients Treated With Electronic Brachytherapy (eBx) At University of Wisconsin Riverview Cancer Center

... skin cancer include several types of surgery, topical treatments and radiation therapy. The location and extent of the cancer impacts which treatment option is best for each patient. Whether in combination with surgery or as a stand alone treatment, electronic brachytherapy enables clinicians to administer...

Schering-Plough Announces U.S. Filing of Mometasone Furoate/Formoterol Fumarate Combination for the Maintenance Treatment of Asthma

...ng-Plough Research Institute. "If approved by the FDA, the mometasone fuorate/formoterol combination would represent an important additional treatment option for physicians and their patients and further strengthen Schering-Plough's portfolio of respiratory products." Combination products containin...

Schering-Plough Expands Vicriviroc Phase II Study in Treatment-Naive Patients With HIV

...ate)(3) plus ritonavir-boosted atazanavir, which is a currently recommended option for first-line therapy. Atazanavir is a product in the protease inhibitor ...itonavir was selected for use in this study because it is recommended as an option for first-line therapy in both the International AIDS Society and Departmen...

Bioniche Life Sciences Inc. and Endo Pharmaceuticals Sign Licensing Agreement for Urocidin(TM)

...daq: ENDP ) jointly announced today that Endo has licensed from Bioniche the exclusive rights to develop and market Urocidin(TM) in the U.S. with an option for global rights. Urocidin is a patented formulation of Mycobacterial Cell Wall-DNA Complex (MCC) developed by Bioniche for the treatment of non-mu...

Calixa Therapeutics Announces Initiation of Phase 2 Clinical Trial of Its Antibiotic, CXA-101, in Patients with Complicated Urinary Tract Infections

...nce, we are working diligently to expedite the development of CXA-101. We are fully committed to providing patients and physicians with a much needed option for the treatment of life-threatening infections caused by gram-negative bacteria." About Calixa Therapeutics Calixa Therapeutics Inc. is a b...

New Data Supports Significant Economic and Clinical Value of MENOPUR(R) in IVF

... work is likely to have a major impact on the decision-making process with respect to IVF treatment. The study showed that HP-hMG is a more attractive option than rFSH within a fixed budget, as it offers considerable cost savings over rFSH, not only in terms of costs per treatment cycle, but also in costs p...

SIMPONI(TM) (golimumab) Receives Positive Opinion From CHMP for Once-Monthly Subcutaneous Treatment of Rheumatoid Arthritis, Psoriatic Arthritis and Ankylosing Spondylitis

...nt, Clinical R&D, Centocor Research & Development, Inc. "We are optimistic that SIMPONI will be a welcome addition as a new anti-TNF treatment option for rheumatologists, and adults living with these inflammatory conditions who are seeking an effective and convenient therapy." Upon receipt o...

Transave Receives $2.2 Million Cystic Fibrosis Foundation Award for Development of ARIKACE(TM)

...ollowed and supported Transave's work in this area from the beginning, and we are excited to play a role in potentially bringing another new treatment option to CF patients," said Robert J. Beall, Ph.D., President and CEO of the Cystic Fibrosis Foundation. "The potential for ARIKACE is encouraging, both in...

Jazz Pharmaceuticals and UCB Announce Second Phase III Study of Sodium Oxybate in Patients With Fibromyalgia Meets Primary Endpoints

...UCB. "The positive results of the two Phase III trials are encouraging and suggest that subject to regulatory approval, this may offer a new treatment option for people with fibromyalgia." Only preliminary top-line efficacy and safety data are available at this time. Further analyses are planned, inclu...

Spherix Announces Positive Phase 2 Study Results

... an average of 0.3. "The results of this ongoing Phase 2 study are encouraging and reaffirm our belief that Naturlose may be a valuable treatment option for patients with Type 2 diabetes," said Dr. Claire Kruger, CEO of Spherix. "Naturlose, administered at three separate low doses, proved to be effect...

Amicus Therapeutics Commences Phase 3 Trial Evaluating Amigal(TM) for the Treatment of Fabry Disease

...ivotal study and are confident we have set the stage for a successful Phase 3 study. We continue to believe that Amigal may be an important treatment option for patients who suffer with Fabry disease and a significant step forward for them and their families." Raphael Schiffmann, MD, Director of the I...

Responses After Completion of Therapy Increase Pixantrone Complete Remission (CR)/Unconfirmed Complete Remission (CRu) Rate to 24% and Overall Response Rate (ORR) to 40% Compared to 7% and 14% for Comparator Agents in Phase III EXTEND Trial in 3rd Line Th

... "We plan to request priority review of the NDA from the FDA as we believe that pixantrone would provide patients and physicians with a compelling new option in treating this disease." Review of Pixantrone Clinical Studies in Indolent non-Hodgkin's lymphoma Additionally, data from two previou...

Urologist and Allergist Explore Link Between Allergies and Interstitial Cystitis

...eatment options and research directions WASHINGTON, June 19 /PRNewswire-USNewswire/ -- Allergy testing and treatment may offer a new therapeutic option for many patients with interstitial cystitis (IC). IC is a severely painful bladder condition affecting as many as 8 million women and 1.5 million men...

Study Demonstrates Efficacy of Pitavastatin in Elderly Patients

... Pitavastatin represents important treatment option for more vulnerable populations BOSTON, June 16 /PRNewswire/ -- New da...y difference across all doses, and may represent a more favorable treatment option for such target populations." The Phase III, active-controlled study w...

UPCI Joins ExCell Research Study Using Stem Cells for Leukemia and Lymphoma Patients

...nors. Cord blood could be an alternative of choice. Previous research has shown that umbilical cord blood stem cells offer a viable therapeutic option for leukemia and lymphoma patients without the necessity of a matched donor. Umbilical cord blood has two important advantages - it is a readily avail...

Data Demonstrated ACTEMRA(R) (tocilizumab) Significantly Inhibited Progression of Structural Joint Damage in Rheumatoid Arthritis Patients

...upport the use of ACTEMRA as a long-term treatment option for patients with moderately to severely active RA...ich suggests that it may be an effective treatment option for many RA patients." Additionally, the one-...on of IL-6 reinforce ACTEMRA as a viable treatment option for patients with RA," said Kenneth Bahrt, M.D., G...

Merz Pharmaceuticals Announce Three Studies of NT-201 - (Botulinum neurotoxin type A Free From Complexing Proteins)

..., Vice President of Medical Affairs, Merz Pharmaceuticals, USA said, "These findings suggest Xeomin, the brand name for NT-201 in Europe, may be a new option in the treatment of movement disorders in the United States." First Study -Title Efficacy and safety of NT-201 (Xeomin(R), botulinum neurot...

New Heart Ultrasound Research Reveals Life-Saving Treatment Alternatives and Advancements for Heart Patients

...hocardiograms. Studies detail the following: A nonsurgical option for common heart procedures Lack of adherence to guidelines leave s...leases and study abstracts, please visit SeeMyHeart.org. NONSURGICAL option FOR COMMON HEART PROCEDURE OFFERS EFFECTIVE RESULTS WITH LESS RECOVERY TIME...

Micromet's Blinatumomab Achieves Primary Endpoint in Phase 2 Study with Acute Lymphoblastic Leukemia Patients

...s entered into an option, collaboration and license agreement with Bayer Schering Pharma AG under which Bayer Schering Pharma was granted an exclusive option to license a specified BiTE antibody against an undisclosed solid tumor target. Micromet's preclinical product pipeline includes several novel BiTE ...

Micromet Presents Update on Blinatumomab's Response Rate and Duration in a Phase 1 Study in Non-Hodgkin's Lymphoma Patients

...s entered into an option, collaboration and license agreement with Bayer Schering Pharma AG under which Bayer Schering Pharma was granted an exclusive option to license a specified BiTE antibody against an undisclosed solid tumor target. Micromet's preclinical product pipeline includes several novel BiTE ...

Merz Pharmaceuticals Announces Results of Clinical Trials with NT-201(Botulinum neurotoxin type A free from complexing proteins) at Annual Movement Disorders Society Meeting

...ogies including stroke, brain injury, spinal cord injury, multiple sclerosis or cerebral palsy, warranting additional studies as a potential treatment option for a wide scope of patients." NT-201 is a neurotoxin therapy free from complexing proteins due to a combination of high biologic activity with l...

SCAI Statement on the BARI 2D Trial (Bypass Angioplasty Revascularization Investigation With Diabetes Trial) Presented at the American Diabetes Association (ADA) Annual Scientific Sessions and Published in The New England Journal of Medicine

...t as one of the first steps to manage disease. But for many patients, medical therapy is not enough, and revascularization may be a safe and effective option for improving their quality of life." "Further research is needed on what optimal medical therapy truly is for patients," said Robert Chilton, ...

Lilly Announces Positive Phase II Data on Investigational Medicine for Patients with Type 2 Diabetes

...istered once weekly and demonstrated significant glucose-lowering activity and reduced body weight, supporting its potential to become a new treatment option for the millions of people with type 2 diabetes." About LY2189265 LY2189265, a once-weekly injection, is a novel-engineered fusion protein, c...

Arena Pharmaceuticals Announces Lorcaserin Data Demonstrating Highly Significant Categorical and Absolute Weight Loss and Improvements in Secondary Endpoints Associated with Cardiovascular Risk

...erin is currently being evaluated in a Phase 3 program expected to enroll approximately 7,800 patients and potentially represents a targeted treatment option for the millions of patients who need to better manage their weight. Arena has patents that cover lorcaserin in the US and other jurisdictions, which ...

AFRESA(R) Phase 3 Pulmonary Function Safety Data in Patients with Diabetes Presented at ADA

...te Vice President and Chief Scientific Officer, MannKind Corporation. "Our encouraging findings indicate that AFRESA may be a promising new treatment option with less weight gain and lower risk of hypoglycemia compared with current mealtime insulin therapy." AFRESA is a novel, ultra rapid acting mealt...
Other Tags
(Date:1/22/2015)... , Jan. 16, 2015  A man-made form of insulin ... other mental capabilities in adults with mild cognitive impairment ... led by researchers at Wake Forest Baptist Medical Center. ... with amnesic mild cognitive impairment (MCI) or mild to ...
(Date:1/22/2015)... DUBLIN , Jan. 22, 2015 Research and ... the addition of the "Global Wearable Technologies ... Growth, Share, Overview, Trends and Forecast 2014-2020" ... Wearable Technologies are smart devices that can be ...
(Date:12/22/2014)... Dec. 22, 2014 Research and Markets ... the "The Global Watermarking and Fingerprinting Markets" ... http://photos.prnewswire.com/prnh/20130307/600769 This insight ... watermarking and fingerprinting markets. Watermarking aims to control ...
Breaking Biology News(10 mins):Nasal Spray with Insulin Equivalent Shows Promise as Treatment for Adults with Mild Cognitive Impairment, Alzheimer's Dementia 2Nasal Spray with Insulin Equivalent Shows Promise as Treatment for Adults with Mild Cognitive Impairment, Alzheimer's Dementia 3Global Wearable Technologies Market and Applications, Opportunities, Industry Analysis, Segmentation, Size, Growth, Share, Overview, Trends and Forecast 2014-2020 2The Global Watermarking and Fingerprinting Markets 2
(Date:1/22/2015)... January 22, 2015 IsoComforter, Inc. has introduced ... with patented IsoTube design to treat specific body parts and ... most progressive and easy to use patented cold therapy machine ... sports related orthopedic and muscle injuries. IsoComforter has become ...
(Date:1/22/2015)... 2015 Payday lending practices in four ... cause financial distress to the states that permit them, ... University’s Center on Race and Wealth. , While they ... payday loans at the same time substantially depress economic ...
(Date:1/22/2015)... As interest in the value of spiritual support ... Rev. Eric J. Hall , president and CEO of ... be the keynote speaker on January 27 at an international ... , The conference, “Hope and Resilience: Innovative and Interdisciplinary Spiritual ...
(Date:1/22/2015)... Compare-autoinsurance.org has released a new blog post presenting a list ... policy . , Some types of vehicles cannot be covered ... released blog post to see if their vehicle qualifies for auto ... some of the cars that cannot be covered by a plan. ...
(Date:1/22/2015)... 2015 Step into a macabre world ... Museum of Virginia. Wicked Plants, the Museum’s latest featured ... 75 poisonous, carnivorous and diabolical plants inside of a ... uncover the biochemical, physical and neurological processes between botanicals ...
Breaking Medicine News(10 mins):Health News:IsoComforter Introduces Best of Class Cold Therapy Product to the Worldwide Market 2Health News:Howard University Spotlights the Economic Impact of Payday Lending in Southern States 2Health News:HealthCare Chaplaincy CEO to Keynote Spiritual Care Summit in Israel 2Health News:HealthCare Chaplaincy CEO to Keynote Spiritual Care Summit in Israel 3Health News:Some Vehicles Cannot Be Covered By An Auto Insurance Policy! 2Health News:Wicked Plants are taking over the Science Museum of Virginia 2
Other Contents